Alex Van der Eb is a Dutch molecular biologist who has made significant contributions to the field of molecular genetics. He is best known for his work on the development of the adenovirus vector, a tool used to introduce new genetic material into cells. This technology has been widely used in gene therapy and the development of recombinant vaccines, such as the AstraZeneca COVID-19 vaccine.
Dr. Van der Eb obtained his Ph.D. in molecular biology from the University of Leiden in the Netherlands. Over the course of his career, he has held various research and academic positions. He is also the founder of several biotechnology companies, including Crucell, which was later acquired by Johnson & Johnson.
In addition to his work on adenovirus vectors, Dr. Van der Eb has made significant contributions to understanding the role of tumor suppressor genes in cancer development, particularly in the case of the p53 gene. His research has led to a better understanding of the molecular mechanisms that underlie cancer, and has helped in the development of new therapeutic strategies for the disease.